Froese Logan, Dian Joshua, Batson Carleen, Gomez Alwyn, Alarifi Norah, Unger Bertram, Zeiler Frederick A
Biomedical Engineering, Faculty of Engineering, University of Manitoba, Winnipeg, Manitoba, Canada.
Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Neurotrauma Rep. 2020 Nov 6;1(1):157-168. doi: 10.1089/neur.2020.0028. eCollection 2020.
The impact of vasopressor and sedative drugs on cerebrovascular reactivity in traumatic brain injury (TBI) remains unclear. The aim of this study was to evaluate the impact of changes of doses of commonly administered sedation (i.e., propofol, fentanyl, and ketamine) and vasopressor agents (i.e., norepinephrine [NE], phenylephrine [PE], and vasopressin[VSP]) on cerebrovascular reactivity and compensatory reserve in patients with moderate/severe TBI. Using the Winnipeg Acute TBI Database, we identified 38 patients with more than 1000 distinct changes of infusion rates and more than 500 h of paired drug infusion/physiology data. Cerebrovascular reactivity was assessed using pressure reactivity index (PRx) and cerebral compensatory reserve was assessed using RAP (the correlation [R] between pulse amplitude of intracranial pressure [ICP; A] and ICP [P]). We evaluated the data in two phases. First, we assessed the relationship between mean hourly dose of medication and its relation to both mean hourly index values, and time spent above a given index threshold. Second, we evaluated time-series data for each individual dose change per medication, assessing for a statistically significant change in PRx and RAP metrics. The results of the analysis confirmed that, overall, the mean hourly dose of sedative (propofol, fentanyl, and ketamine) and vasopressor (NE, PE, and VSP) agents does not impact hourly cerebrovascular reactivity or compensatory reserve measures. Similarly, incremental dose changes in these medications in general do not lead to significant changes in cerebrovascular reactivity or compensatory reserve. For propofol with incremental dose increases, in situations where PRx is intact (i.e., PRx <0 prior), a statistically significant increase in PRx was seen. However, this may not indicate deteriorating cerebrovascular reactivity as the final PRx (∼0.05) may still be considered to be intact cerebrovascular reactivity. As such, this finding with regards to propofol remains "weak." This study indicates that commonly administered sedative and vasopressor agents with incremental dosing changes have no clinically significant influence on cerebrovascular reactivity or compensatory reserve in TBI. These results should be considered preliminary, requiring further investigation.
血管升压药和镇静药物对创伤性脑损伤(TBI)患者脑血管反应性的影响尚不清楚。本研究的目的是评估常用镇静药物(即丙泊酚、芬太尼和氯胺酮)和血管升压药(即去甲肾上腺素[NE]、去氧肾上腺素[PE]和血管加压素[VSP])剂量变化对中度/重度TBI患者脑血管反应性和代偿储备的影响。利用温尼伯急性TBI数据库,我们确定了38例患者,其输注速率有1000多次不同变化,且有500多小时的配对药物输注/生理数据。使用压力反应指数(PRx)评估脑血管反应性,使用RAP(颅内压[ICP]的脉搏振幅[A]与ICP[P]之间的相关性[R])评估脑代偿储备。我们分两个阶段评估数据。首先,我们评估了每小时药物平均剂量与其与每小时平均指数值以及高于给定指数阈值的时间之间的关系。其次,我们评估了每种药物每次剂量变化的时间序列数据,评估PRx和RAP指标的统计学显著变化。分析结果证实,总体而言,镇静药物(丙泊酚、芬太尼和氯胺酮)和血管升压药(NE、PE和VSP)的每小时平均剂量不会影响每小时的脑血管反应性或代偿储备指标。同样,这些药物的剂量递增变化一般不会导致脑血管反应性或代偿储备的显著变化。对于丙泊酚剂量递增的情况,在PRx正常(即之前PRx<0)的情况下,可观察到PRx有统计学显著增加。然而,这可能并不表明脑血管反应性恶化,因为最终的PRx(约0.05)仍可能被认为是正常的脑血管反应性。因此,关于丙泊酚的这一发现仍然“不明确”。本研究表明,常用的镇静药物和血管升压药剂量递增变化对TBI患者的脑血管反应性或代偿储备没有临床显著影响。这些结果应被视为初步结果,需要进一步研究。